Efficacy News and Research

RSS

Targeted therapy found to be effective at shrinking tumors in patients with nonsmall-cell lung cancer

An international team of researchers has found that selpercatinib, a drug that precisely targets cancers driven by mutations or alterations in the gene RET, was effective at shrinking tumours in patients with nonsmall cell lung cancer (NSCLC), with a majority of patients living for more than a year without disease progression.

28 Sep 2020

Study reveals underrepresentation of older people in COVID-19 trials

A study published today in the Journal of the American Medical Association Internal Medicine revealed that older persons are highly likely to be excluded from the majority of COVID-19 trials that seek to establish effective treatments, as well as find a preventive vaccine.

28 Sep 2020

Researchers study placebo effect in nausea treatment at the molecular level

The molecular bases of the placebo effect are poorly understood. A team led by Ludwig-Maximilians-Universitaet in Munich researcher Karin Meissner has now studied the phenomenon in the context of nausea, and identified specific proteins that correlate with its favorable impact.

28 Sep 2020

Clover Biopharma's new trimeric subunit vaccine candidate prevents COVID-19 in monkeys

The vaccine candidate produced a high level of neutralizing antibodies in animal models. Rhesus macaques immunized with the vaccine candidate showed reduced viral loads in the lungs. The research is published on the preprint server bioRxiv.

28 Sep 2020

Special formulation of inhaled niclosamide may be effective against SARS-CoV-2

Now in new research published on the preprint server bioRxix*, a novel formulation of the drug Niclosamide (NIC) is observed to be effective against SARS-CoV-2 and MERS-CoV in mouse models; it also protects against methicillin-resistance Staphylococcus aureus pneumonia and inflammatory lung damage.

28 Sep 2020

Seniors the optimal target for SARS-CoV-2 vaccination

ith several vaccines already in stage 3 clinical trials, a study by University of Warwick researchers and published on the preprint server medRxiv in September 2020 discusses the use of computer modeling techniques in order to achieve optimal vaccine coverage.

28 Sep 2020

Risk factors for mortality among hospitalized patients with COVID-19

A new study by scientists at biotechnology company Genentech, Inc., and published on the preprint server medRxiv in September 2020 attempts to identify the factors which may shape the risk for death in COVID-19 disease.

27 Sep 2020

College re-openings could cause 3,200 extra cases of COVID-19 per day in the US

A new report published in the preprint server medRxiv in September 2020 shows the close relationship between the re-opening of colleges, especially those drawing students from high-incidence areas, and those offering in-person instruction, and the significant increase in the incidence of COVID-19 among students and the community.

27 Sep 2020

How many "listeners" a nerve cell has is strictly regulated, shows study

How many "listeners" a nerve cell has in the brain is strictly regulated. This is shown by an international study led by the University College London and the universities of Bonn, Bordeaux and Milton Keynes (England).

26 Sep 2020

New drug offers hope for young boys with Duchenne muscular dystrophy

A new drug offers hope for young boys with the progressive neuromuscular disease Duchenne muscular dystrophy (DMD) by potentially offering an alternative to high-dose glucocorticoids that have significant side effects.

25 Sep 2020

Study assesses cardiovascular and renal outcomes for ertugliflozin in patients with type 2 diabetes

A new study led by a cardiologist from Brigham and Women's Hospital has assessed the cardiovascular and renal outcomes for ertugliflozin, an SGLT2 inhibitor prescribed for patients with type 2 diabetes to help them control blood sugar levels

25 Sep 2020

Berlin researchers are pursuing the development of passive vaccination

Researchers at the German Center for Neurodegenerative Diseases (DZNE) and Charité - Universitätsmedizin Berlin have identified highly effective antibodies against the coronavirus SARS-CoV-2 and are now pursuing the development of a passive vaccination.

25 Sep 2020

Experimental cancer drug AR-12 inhibits SARS-CoV-2 virus

Nine months into the global pandemic, which has infected more than 32 million people, there is still no approved effective and safe drug or vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

24 Sep 2020

These secret safety panels will pick the COVID vaccine winners

Most Americans have never heard of Dr. Richard Whitley, an expert in pediatric infectious diseases at the University of Alabama-Birmingham.

24 Sep 2020

AI used to define the cytokine storm implicated in fatal COVID-19

A new study published on the preprint server bioRxiv* in September 2020 reports the use of artificial intelligence (AI) to identify an invariant or universal host immune response found in all viral pandemics so far. The association of this response with severe COVID-19 phenotypes indicates a new understanding of the human immune response in viral pandemics.

24 Sep 2020

Many people are overestimating their risk of becoming seriously ill and dying from COVID-19

A new National Science Foundation-funded survey of six states has found that during the past two months, more people are wearing masks, vaccine uncertainty is on the rise, and many people are overestimating their risk of becoming seriously ill and dying from COVID-19.

24 Sep 2020

Researchers develop 'Trojan horse' approach to destroy cancer cells

Cancer cells are killed in lab experiments and tumour growth reduced in mice, using a new approach that turns a nanoparticle into a 'Trojan horse' that causes cancer cells to self-destruct, a research team at the Nanyang Technological University, Singapore (NTU Singapore) has found.

23 Sep 2020

UV-C irradiation rapidly inactivates SARS-CoV-2 on surfaces

Researchers at University Hospital Tübingen, Germany, have shown that ultraviolet C (UV-C) irradiation effectively inactivates surface-dried preparations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

23 Sep 2020

A subunit SARS-CoV-2 vaccine may offer broader protection against virus

A new study published in the preprint server bioRxiv in September 2020 reports on the structure of this protein, as revealed by cryo-electron microscopy (cryoEM).

23 Sep 2020

Acquisition of a natural mutation primes SARS-CoV-2 for neutralization by a cross-reactive antibody

A team of scientists from the United States reveals that the acquisition of a natural mutation makes severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) susceptible to neutralization by a cross-reactive SARS-CoV antibody. The study is currently available on the bioRxiv* preprint server.

22 Sep 2020